Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent an important advancement in nephrology, offering benefits far beyond glycemic control in individuals with type 2 diabetes mellitus (T2DM). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.